B
BCAB
BioAtla, Inc. Common Stock
$1.74
Current Price
1W
1M
3M
6M
1Y
All
AI analysis
Read what the AI thinks of BioAtla, Inc. Common Stock in the app.
Analyses are generated by AI from public data and are not investment advice.
Get the app
Key figures
Dividend per share
—
Yield
—
EPS
-$25.56
P/E
—
Data as of Oct 8
Why it matters for the long term
Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.
Upcoming events
Quarterly earnings
Expected EPS: -$0.14
Nov 11
Posts
No posts about BCAB yet.
About BioAtla, Inc. Common Stock
BioAtla is a small biotech company trying to develop new cancer treatments. It uses a technology it calls "Conditionally Active Biologic" antibodies, designed to attack tumors while leaving healthy tissue alone, in the hope that this causes fewer side effects than older cancer drugs. The company has no approved product for sale yet, so its income comes almost entirely from a couple of research partnerships rather than actual drug sales, and it pays for its clinical trials mainly by issuing new stock and borrowing against future stock sales.